has provided a positive opinion for Advanced Therapy Medicinal Product (ATMP) classification for the company's gene therapy candidate OCU400 to treat Retinitis pigmentosa. A phase 3 study of ...

Ocugen, Inc. has announced that the European Commission has given a positive opinion for the classification of its gene therapy product, OCU400, as an Advanced Therapy Medicinal Product (ATMP) by ...

Belgian university hospitals UZ Leuven and KU Leuven are investing €14 million in a new facility for the production of Advanced Therapy Medicinal Products ... is a good example of a structure ...

Here, we provide transplant and advanced-therapy medicinal product (ATMP ... specific conditions that are expensive to maintain. For example, an HVAC [heating, ventilation, and air conditioning ...

Despite its significant potential, Europe trails North America and the Asian Pacific in Advanced Therapy Medicinal Product (ATMP) development, clinical trials, and investment. Belgium however ...

The Cell and Gene Therapy Catapult (CGT Catapult) presented the data in its UK 2024 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database. The UK maintained its position as a highly ...

Committee for Advanced Therapies for OCU400 Advanced Therapy Medicinal Product classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa indication.

However, since the introduction of this therapy ... highlights the complexity of medicinal product safety and the challenge of assessing potential risks of these advanced therapeutics.